ClinicalTrials.gg
CompletedNCT05467709Updated Jul 20, 2022

Study To Evaluate The Effect Of Multiple Doses of CTP-543 On The Pharmacokinetics Of Single Doses of Midazolam In Healthy Subjects

A Phase 1 interventional study of Midazolam and CTP-543 in Health Volunteers, sponsored by Concert Pharmaceuticals. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-07-20.

Sponsored by Concert Pharmaceuticals (part of Sun Pharmaceutical Industries Limited) · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Jun 2022, 4 years 4 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 60 Years
Sex
All
01

Study summary

This is a single center, Phase 1, open-label, fixed-sequence, drug-drug interaction study to determine the effect of CTP-543 on the pharmacokinetics (PK) of midazolam in healthy adult subjects

02

Conditions studied

  • Health Volunteers

Keywords

  • CTP-543
03

In context

Lead sponsor

Concert Pharmaceuticals is the lead sponsor of 33 studies on the registry; none are open to participants now.

Of its 20 completed or terminated interventional studies of FDA-regulated products, 7 (35%) have results posted.

First submitted before Concert Pharmaceuticals became part of Sun Pharmaceutical Industries Limited.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy, adult, male or female, aged 18-60
  • Non-smoker who has not used nicotine-containing products for at least 3 months prior to the first dosing
  • (BMI) ≥ 18.0 and ≤ 32.0 kg/m2 at screening
  • If of reproductive age, willing and able to use a medically highly effective form of 4 weeks prior to first dose, during the study and for 30 days following last dose of study medication
  • Capable of giving and complying with study procedures

Exclusion criteria

Exclusion Criteria:

  • History or presence of medical or psychiatric condition or disease
  • History or presence of alcohol or drug abuse within the past 2 years prior to the first dosing
  • Presence or history of significant gastrointestinal, liver or kidney disease, or any other condition that is known to interfere with drug absorption, distribution, metabolism or excretion, or known to potentiate or predispose to undesired effects
  • History of prolonged syndrome or a QTc interval with Fridericia's correction (QTcF) > 450 msec for males or QTcF > 470 msec for females at screening visit or prior to the first dosing
  • Abnormal liver function at screening
  • Females who are nursing, pregnant, or planning to become pregnant while in the study, and for 30 days after last dose of study drug
  • Positive results for coronavirus infection (COVID-19) at screening or check-in
  • Positive drug or alcohol results at screening or check-in
  • Positive results at screening for (HIV), surface antigen (HBsAg) or virus (HCV)
  • Participation in another clinical study within 30 days prior to, and 30 days after the first dosing.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    CTP-543

    Subjects will receive a single 2 mg dose of midazolam on Day 1. Starting on Day 3, 12 mg dose of CTP-543 will be administered (q12 hrs) for 14 consecutive days (up to Day 16). On Day 16, subjects will be co-administered a single 2 mg midazolam dose along with the morning dose of CTP-543. The second dose of CTP-543 will be administered as scheduled on Day 16.

    Drug: Midazolam · Drug: CTP-543

Interventions

  • 2 mg Day 1 and Day 16

  • 12 mg q12 hour for 14 consecutive days starting on Day 3

06

What researchers measure

Primary outcomes

  1. Cmax

    Maximum observed concentration

    Time frame: Day 14, 15, 16, Discharge (Day 17)

  2. Tmax

    Time to reach maximum observed concentration

    Time frame: Day 14, 15, 16, Discharge (Day 17)

  3. AUC0-inf

    Area under the concentration-time curve from time 0 extrapolated to infinity

    Time frame: Day 14, 15, 16, Discharge (Day 17)

  4. AUC0-t

    Area under the concentration-time curve from time 0 to the time of the last observed/measured non-zero concentration

    Time frame: Day 14, 15, 16, Discharge (Day 17)

  5. λz

    Terminal elimination rate constant

    Time frame: Day 14, 15, 16, Discharge (Day 17)

  6. t1/2

    Apparent terminal half-life

    Time frame: Day 14, 15, 16, Discharge (Day 17)

  7. CL/F

    Apparent total plasma clearance (Midazolam only)

    Time frame: Day 1, 2, 16, Discharge (Day 17)

  8. Vz/F

    Apparent volume of distribution (Midazolam only)

    Time frame: Day 1, 2, 16, Discharge (Day 17)

Secondary outcomes

  1. Assessment of Safety and Tolerability following administration of CTP-543

    Number of adverse events, including abnormal clinical laboratory findings, abnormal physical examinations, abnormal ECGs and abnormal vital signs tabulated for each subject

    Time frame: Screening (within 21 days prior to Day 1) through follow-up (approximately 7 days after last study drug administration)

07

Study locations

1 site
  • Clinical Pharmacology of Miami, LLC
    Miami, Florida 33014, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2022 to primary completion in Jun 2022, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2022
First posted
Jul 20, 2022
StartActual
Jun 21, 2022
Primary completionActual
Jun 30, 2022
CompletionActual
Jul 7, 2022
Last update
Jul 20, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 20, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05467709
Responsible party
Sponsor
First posted
Jul 20, 2022
Start date
Jun 21, 2022
Primary completion
Jun 30, 2022
Completion
Jul 7, 2022
Last update
Jul 20, 2022

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Deuruxolitinib

Start the discussion